key: cord-0721224-rs91gc6n
authors: Kayikcioglu, Meral; Tokgozoglu, Lale; Tuncel, Ozlem Kuman; Pirildar, Sebnem; Can, Levent
title: Collateral damage of the COVID-19 pandemic on the management of homozygous familial hypercholesterolemia
date: 2021-06-04
journal: J Clin Lipidol
DOI: 10.1016/j.jacl.2021.02.003
sha: 35d54eae67c5d308dc2bb869e345baf7976b4f06
doc_id: 721224
cord_uid: rs91gc6n

nan

Collateral damage of the COVID-19 pandemic on the management of homozygous familial hypercholesterolemia With our 20-year of experience on lipoprotein apheresis (LA), 1,2 we fully agree with Vuorio et al's comment 3 regarding the vital role of continued LA in homozygous familial hypercholesterolemia (HoFH) patients during the COVID-19 pandemic. Our recent survey 4 was conducted to determine the collateral damage that the pandemic caused to provide insight to the impact of COVID-19 outbreak on lifestyle, anxiety levels, and management of HoFH in terms of LA and lipid-lowering therapy (LLT). The results of our descriptive survey depicted that management of patients with HoFH with regard to heart-healthy lifestyle and access to LA has significantly deteriorated during the pandemic even in a country where LA is full reimbursed and widely available. 4, 5 Our study revealed that although LA was accessible in most of the centers throughout the country during the pandemic, most of the patients (75%) were not attending their LA sessions due to fear of contracting coronavirus. 4 LA is not only the most effective means of low-density lipoprotein cholesterol (LDL-C) lowering, but also effectively decreases the number of inflammatory proteins including cytokines and thrombogenic factors and improves endothelial function. 2,6,7 LA also has impact on gene translation and transcription by affecting cytokine receptor functions. 8 Therefore, apheresis is also used as a therapeutic modality in patients with a cytokine release storm during the course of COVID-19. 9 However, LA is a hospital or healthcare center dependent treatment that can be easily disrupted by a disaster as we experienced during the COVID-19 pandemic either due to the overload of the medical system by COVID-19 patients or the reluctance of the patients to visit the hospital in fear of getting infected during the procedures. 1, 4 Even patients with acute coronary syndromes have avoided admitting to hospital during the pandemic as several reports have shown all over the world. 10, 11 We demonstrated that many HoFH patients could not get access to LA therapy during the pandemic exposing them to increased risk of cardiovascular events. 4 It is well established that the on-treatment LDL-C level is the major determinant of survival in HoFH. 12 Therefore, we emphasize in our paper the importance of continued regular effective therapy. Moreover, as we mentioned in our manuscript the role of National Scientific Societies and, more importantly, patient organizations is vital for increasing the awareness of patients, physicians, and public on the importance of LA and effective LLT in HoFH patients. Social media could be very powerful in overcoming patient/public fear of contracting the coronavirus leading to medical care avoidance. Our findings also denoted the importance of being in contact with the patients and providing the necessary information in terms of telemedicine for adherence to the therapy.

In addition to apheresis, access to new effective LLT provided via randomized controlled trial enrollment was also hampered by the pandemic. Fortunately, access to novel LLT was uninterrupted because the Ministry of Health took precautions to overcome this by homedelivery of medications (and care) and complete visits by telemedicine.

Since the publication of our paper, we have conducted educational programs with patient organizations such as FH Europe as well as the Ministry of Health to raise awareness. This has resulted in a slow but consistent increase in the number of patients seeking healthcare. This experience has taught us how to handle the different aspects and collateral damages of the pandemic.

LDL Apheresis and Lp (a) Apheresis: A Clinician's Perspective

Long-term follow-up in patients with homozygous familial hypercholesterolemia; 13-year experience of a university hospital lipid clinic

Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19?

Negative impact of COVID-19 pandemic on the lifestyle and management of patients with homozygous familial hypercholesterolemia

A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry). Atherosclerosis

Current Role of Lipoprotein Apheresis

Clinical management, psychosocial characteristics, and quality of life in patients with homozygous familial hypercholesterolemia undergoing LDLapheresis in Turkey: Results of a nationwide survey

Lipid and low-density-lipoprotein apheresis. Effects on plasma inflammatory profile and on cytokine pattern in patients with severe dyslipidemia

Potential of therapeutic plasmapheresis in treatment of COVID-19 patients: Immunopathogenesis and coagulopathy

Worrying decrease in hospital admissions for myocardial infarction during the COVID-19 pandemic

Treatment delays and inhospital outcomes in acute myocardial infarction during the COVID-19 pandemic: A nationwide study

Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol